Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study - Qin, S; Chen, Z; Fang, W (Journal of Clinical Oncology, 2022)
et al.